| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Ribozyme Pharmaceuticals, Inc., Boulder, Colorado 80301 [P. A. Pa., K. S. Bo., A. M. G., A. A., K. S. Bl., S. L. G., K. L. J., L. E. A., F. E. W., M. A. R., T. J. P.], and Chiron Corp., Emeryville, California 94608 [P. A. Pi., R. J. T., C. C.]
Chemically stabilized hammerhead ribozymes are nuclease-resistant, RNA-based oligonucleotides that selectively bind and cleave specific target RNAs. Due to their potential for specifically inhibiting gene expression, ribozymes are being investigated for therapeutic applications as well as for the elucidation of gene function. In particular, we have investigated ribozymes that target the mRNA of the vascular endothelial growth factor (VEGF) receptors because VEGF signaling is an important mediator of tumor angiogenesis and metastasis. Here we report pharmacodynamic studies testing anti-Flt-1 (VEGFR-1) and anti-KDR (VEGFR-2) ribozymes in animal models of solid tumor growth and metastasis. Ribozymes targeting either Flt-1 or KDR significantly inhibited primary tumor growth in a highly metastatic variant of Lewis lung carcinoma. However, only treatment with the anti-Flt-1 ribozyme resulted in a statistically significant and dose-dependent inhibition of lung metastasis in this model. The anti-Flt-1 ribozyme was then tested in a xenograft model of human metastatic colorectal cancer in which significant inhibition of liver metastasis was observed. Taken together, these data represent the first demonstration that synthetic ribozymes targeting VEGF receptor mRNA reduced the growth and metastasis of solid tumors in vivo.
This article has been cited by other articles:
|
|
 |
|
  R. HUHN, M. S. STAEGE, M. HESSE, B. LIEBIG, and S. E.G. BURDACH Cleavage of the Ewing Tumour-specific EWSR1-FLI1 mRNA by Hammerhead Ribozymes Anticancer Res, June 1, 2009; 29(6): 1901 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, Z. Zhong, J. Huber, R. Bassi, B. Finnerty, E. Corcoran, H. Li, E. Navarro, P. Balderes, X. Jimenez, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6573 - 6584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]
|
|
|
|
|
|
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Weng, P. A. Masci, S. F. Radka, T. E. Jackson, P. A. Weiss, R. Ganapathi, P. J. Elson, W. B. Capra, V. P. Parker, J. A. Lockridge, et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors Mol. Cancer Ther., June 1, 2005; 4(6): 948 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yu, D. Bian, C. Mahanivong, R. K. Cheng, W. Zhou, and S. Huang p38 Mitogen-activated Protein Kinase Regulation of Endothelial Cell Migration Depends on Urokinase Plasminogen Activator Expression J. Biol. Chem., November 26, 2004; 279(48): 50446 - 50454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shiota, M. Sano, M. Miyagishi, and K. Taira Ribozymes: Applications to Functional Analysis and Gene Discovery J. Biochem., August 1, 2004; 136(2): 133 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jiang and J. R. Couchman Perlecan and Tumor Angiogenesis J. Histochem. Cytochem., November 1, 2003; 51(11): 1393 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Beebe, J. P. Jani, E. Knauth, P. Goodwin, C. Higdon, A. M. Rossi, E. Emerson, M. Finkelstein, E. Floyd, S. Harriman, et al. Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for Cancer Therapy Cancer Res., November 1, 2003; 63(21): 7301 - 7309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lu, J. Shen, M. D. Vil, H. Zhang, X. Jimenez, P. Bohlen, L. Witte, and Z. Zhu Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity J. Biol. Chem., October 31, 2003; 278(44): 43496 - 43507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Gao, B.-H. Jiang, S. S. Leonard, L. Corum, Z. Zhang, J. R. Roberts, J. Antonini, J. Z. Zheng, D. C. Flynn, V. Castranova, et al. p38 Signaling-mediated Hypoxia-inducible Factor 1alpha and Vascular Endothelial Growth Factor Induction by Cr(VI) in DU145 Human Prostate Carcinoma Cells J. Biol. Chem., November 15, 2002; 277(47): 45041 - 45048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part II J. Clin. Oncol., July 1, 2002; 20(13): 3016 - 3028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kashani-Sabet, Y. Liu, S. Fong, P.-Y. Desprez, S. Liu, G. Tu, M. Nosrati, C. Handumrongkul, D. Liggitt, A. D. Thor, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice PNAS, March 19, 2002; 99(6): 3878 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kruger, C. Beger, P. J. Welch, J. R. Barber, and F. Wong-Staal C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification Nucleic Acids Res., October 1, 2001; 29(19): e94 - e94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lu, X. Jimenez, H. Zhang, Y. Wu, P. Bohlen, L. Witte, and Z. Zhu Complete Inhibition of Vascular Endothelial Growth Factor (VEGF) Activities with a Bifunctional Diabody Directed against Both VEGF Kinase Receptors, fms-like Tyrosine Kinase Receptor and Kinase Insert Domain-containing Receptor Cancer Res., October 1, 2001; 61(19): 7002 - 7008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Mendel, R. E. Schreck, D. C. West, G. Li, L. M. Strawn, S. S. Tanciongco, S. Vasile, L. K. Shawver, and J. M. Cherrington The Angiogenesis Inhibitor SU5416 Has Long-lasting Effects on Vascular Endothelial Growth Factor Receptor Phosphorylation and Function Clin. Cancer Res., December 1, 2000; 6(12): 4848 - 4858. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Dimmeler and A. M. Zeiher Endothelial Cell Apoptosis in Angiogenesis and Vessel Regression Circ. Res., September 15, 2000; 87(6): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Jarvis, K. S. Bouhana, M. E. Lesch, S. A. Brown, T. J. Parry, D. J. Schrier, S. W. Hunt III, P. A. Pavco, and C. M. Flory Ribozymes as Tools for Therapeutic Target Validation in Arthritis J. Immunol., July 1, 2000; 165(1): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. LaVail, D. Yasumura, M. T. Matthes, K. A. Drenser, J. G. Flannery, A. S. Lewin, and W. W. Hauswirth Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy PNAS, October 10, 2000; 97(21): 11488 - 11493. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
